# Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer

> **NCT02594943** · NA · WITHDRAWN · sponsor: **Region Skane**

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DEVICE:** Boston Scientific Large Capacity with needle Biopsy
- **DEVICE:** Endodrill 1A (BIBBInstruments, Lund, Sweden)

## Key facts

- **NCT ID:** NCT02594943
- **Lead sponsor:** Region Skane
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Too narrow inclusion criteria. Impossible to recruit patients.
- **Last updated:** 2018-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02594943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02594943, "Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02594943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*